By SPC News Staff
Deosumab (Prolia, Amgen) has received a new indication from the FDA to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other osteoporosis therapy.
The approval was based on data from a phase 3 trial that showed patients on glucocorticoid therapy who received deosumab had greater gains in bone